ABL Diagnostics Signs Exclusive Distribution Agreement with AB ANALITICA to Bring Innovative Molecular Biology Assays and Software to All Laboratories in Italy
Woippy, France – ABL Diagnostics (FR001400AHX6 – ABLD), a leading molecular biology company, is pleased to announce its exclusive distribution agreement with AB ANALITICA (https://www.abANALITICA.com/en/) to promote and commercialize ABLD’s assays and software systems to laboratories in Italy. This partnership will bring innovative solutions to laboratories looking to implement PCR assays and downstream analysis systems for infectious diseases such as HIV, viral hepatitis, and respiratory viruses.
With its expertise in molecular biology and its 30 years of experience in Italy, AB ANALITICA has demonstrated a commitment to providing excellence to microbiology laboratories throughout the country. “We are pleased to undertake ABL Diagnostics’ portfolio and offer our clients new solutions for Microbiology Genotyping through DNA sequencing,” said Alberto Bortolato, Sales and Business Development Manager at AB ANALITICA.
ABL Diagnostics’ Head of Diagnostics, Dimitri Gonzalez, added, “Our network of distributors has been constantly expanding for the past decade. We are glad to onboard AB ANALITICA to offer robust and comprehensive solutions to all laboratories in Italy looking to implement simple and innovative sequencing-based solutions.”
The detailed terms of the agreement have not been disclosed.
ABL Diagnostics, a publicly listed company on Euronext’s regulated market in Paris, offers innovative molecular biology assays and end-to-end solutions for PCR detection and genotyping through DNA sequencing. Their products, which cover a wide range of microbiology applications, are used by academic clinical pathology labs, private reference labs, and researchers worldwide.
AB ANALITICA, established in 1990, specializes in the development and sale of diagnostic systems for professional use. With a focus on emerging technologies and the latest medical guidelines, they produce high-quality, innovative, and safe diagnostic systems for microbiology, virology, oncology, and genetics.
For further information, please visit www.abldiagnostics.com or contact Chalom Sayada, General Manager at info@abldiagnostics.com.
Alberto Bortolato, Sales and Business Development Manager at AB ANALITICA, can be reached at info@abanalitica.it for more information about the company.
Forward-Looking Statements:
This press release contains certain forward-looking statements concerning ABL Diagnostics and its business. These statements are based on assumptions that ABL Diagnostics considers reasonable. However, there can be no assurance that these statements will be verified, and they are subject to numerous risks, including those set forth in the “Risk Factors” section of ABL Diagnostics’ universal registration document filed with the AMF on July 12, 2022. The occurrence of these risks could materially differ from the forward-looking statements contained in this press release. This press release and the information contained herein do not constitute an offer or invitation to sell, subscribe, or solicit any order to purchase ABL Diagnostics shares. The distribution of this press release in certain countries may be a violation of local laws. Any persons in possession of this press release must comply with these laws.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.